BioNTech Valuation
| 0A3M Stock | 116.10 4.01 3.58% |
At this time, the firm appears to be overvalued. BioNTech SE shows a prevailing Real Value of USD99.85 per share. The current price of the firm is USD116.1. Our model approximates the value of BioNTech SE from analyzing the firm fundamentals such as Current Valuation of 10.41 B, profit margin of (0.15) %, and Return On Equity of -0.024 as well as examining its technical indicators and probability of bankruptcy.
Enterprise Value 10.4 B | Trailing PE 0.032 |
Overvalued
Today
Please note that BioNTech's price fluctuation is very steady at this time. Calculation of the real value of BioNTech SE is based on 3 months time horizon. Increasing BioNTech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioNTech stock is determined by what a typical buyer is willing to pay for full or partial control of BioNTech SE. Since BioNTech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioNTech Stock. However, BioNTech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 116.1 | Real 99.85 | Hype 115.72 | Naive 111.78 |
The intrinsic value of BioNTech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioNTech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioNTech SE helps investors to forecast how BioNTech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioNTech more accurately as focusing exclusively on BioNTech's fundamentals will not take into account other important factors: BioNTech Cash |
|
BioNTech Total Value Analysis
BioNTech SE is presently projected to have takeover price of 10.41 B with market capitalization of 10.41 B, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BioNTech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.41 B | 10.41 B |
BioNTech Investor Information
About 62.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 52.02. BioNTech SE had not issued any dividends in recent years. Based on the key indicators obtained from BioNTech's historical financial statements, BioNTech SE is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.BioNTech Asset Utilization
One of the ways to look at asset utilization of BioNTech is to check how much profit was generated for every dollar of assets it reports. BioNTech SE shows a negative utilization of assets of -0.0124 percent, losing USD1.24E-4 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of BioNTech SE shows how discouraging it operates for each dollar spent on its assets.BioNTech Profitability Analysis
The company reported the revenue of 3.04 B. Net Income was 9.43 B with profit before overhead, payroll, taxes, and interest of 16.07 B.About BioNTech Valuation
The stock valuation mechanism determines BioNTech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of BioNTech SE based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioNTech. We calculate exposure to BioNTech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioNTech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 486.4 M | 510.8 M |
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.